Catalyst Pharmaceuticals (NASDAQ: CPRX) and Selecta Biosciences (NASDAQ:SELB) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.
Insider and Institutional Ownership
54.7% of Catalyst Pharmaceuticals shares are held by institutional investors. Comparatively, 50.2% of Selecta Biosciences shares are held by institutional investors. 9.6% of Catalyst Pharmaceuticals shares are held by company insiders. Comparatively, 41.9% of Selecta Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This table compares Catalyst Pharmaceuticals and Selecta Biosciences’ top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Catalyst Pharmaceuticals||N/A||N/A||-$18.41 million||($0.21)||-11.67|
|Selecta Biosciences||$210,000.00||1,119.63||-$65.32 million||($3.20)||-3.29|
Catalyst Pharmaceuticals has higher earnings, but lower revenue than Selecta Biosciences. Catalyst Pharmaceuticals is trading at a lower price-to-earnings ratio than Selecta Biosciences, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings and price targets for Catalyst Pharmaceuticals and Selecta Biosciences, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Catalyst Pharmaceuticals presently has a consensus price target of $6.25, indicating a potential upside of 155.10%. Selecta Biosciences has a consensus price target of $30.00, indicating a potential upside of 185.17%. Given Selecta Biosciences’ higher probable upside, analysts plainly believe Selecta Biosciences is more favorable than Catalyst Pharmaceuticals.
This table compares Catalyst Pharmaceuticals and Selecta Biosciences’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
Catalyst Pharmaceuticals has a beta of 1.62, indicating that its stock price is 62% more volatile than the S&P 500. Comparatively, Selecta Biosciences has a beta of -3.56, indicating that its stock price is 456% less volatile than the S&P 500.
Catalyst Pharmaceuticals beats Selecta Biosciences on 8 of the 12 factors compared between the two stocks.
Catalyst Pharmaceuticals Company Profile
Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. Its product candidates include Firdapse, a proprietary form of amifampridine phosphate that has completed Phase III clinical trials for the treatment of patients with lambert-eaton myasthenic syndrome; is in Phase III clinical trial to treat congenital myasthenic syndromes; and is in Phase III clinical trial for the treatment of anti-MuSK antibody positive myasthenia gravis, as well as is in Phase II clinical trial for patients with spinal muscular atrophy type 3. The company is also developing CPP-115, a gamma-aminobutyric acid aminotransferase inhibitor for the treatment of refractory infantile spasms; and CPP-109, a vigabatrin tablet. It has license agreements with Northwestern University, New York University and the Feinstein Institute for Medical Research, and BioMarin Pharmaceutical Inc. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.
Selecta Biosciences Company Profile
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. Its product candidates are in various stages of clinical and preclinical development. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. The Company’s lead product candidate, SEL-212, is a combination of a therapeutic enzyme and its SVP technology designed to be the biologic treatment for gout.
Receive News & Ratings for Catalyst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.